Abpro's Lead Program ABP-102 Highlighted in Celltrion Presentation at J.P. Morgan Healthcare Conference

Abpro's lead program, ABP-102 / CT-P72, was featured in a presentation by global collaboration partner Celltrion at the 44th Annual J.P. Morgan Healthcare Conference. The program recently received FDA IND clearance and is expected to begin a global Phase 1 clinical trial in the first half of 2026. ABP-102 is a multispecific HER2 × CD3 T-cell engager designed to selectively target HER2-overexpressing tumor cells while engaging cytotoxic T cells.